[Form 4] Nektar Therapeutics Insider Trading Activity
Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics (NKTR), reported four sales of company common stock on 09/04/2025 under a Rule 10b5-1 trading plan. The transactions disposed of 1,721 shares in total (793; 432; 189; 307) at weighted average prices of $32.43, $33.60, $34.41, and $35.69 respectively, with execution price ranges disclosed for each lot. Following these sales, the reporting person beneficially owned 17,462 shares (direct ownership). The filing indicates the trades were executed pursuant to a pre-established plan and the filer offers to provide full trade-by-trade details on request.
Jonathan Zalevsky, Chief R&D Officer di Nektar Therapeutics (NKTR), ha effettuato quattro vendite di azioni ordinarie della societ脿 il 04/09/2025 nell'ambito di un piano di negoziazione ai sensi della Rule 10b5-1. Le operazioni hanno riguardato complessivamente 1.721 azioni (lotti da 793, 432, 189 e 307) con prezzi medi ponderati rispettivamente di $32.43, $33.60, $34.41 e $35.69, e sono stati indicati i range dei prezzi di esecuzione per ciascun lotto. Dopo queste cessioni, la persona che ha presentato la comunicazione possedeva beneficiariamente 17.462 azioni (possesso diretto). La comunicazione specifica che le operazioni sono state eseguite conformemente a un piano preesistente e che il dichiarante 猫 disponibile a fornire i dettagli di ciascuna operazione su richiesta.
Jonathan Zalevsky, Director de I&D de Nektar Therapeutics (NKTR), registr贸 cuatro ventas de acciones ordinarias de la compa帽铆a el 04/09/2025 dentro de un plan de negociaci贸n conforme a la Regla 10b5-1. Las transacciones dispensaron un total de 1.721 acciones (lotes de 793, 432, 189 y 307) con precios promedio ponderados de $32.43, $33.60, $34.41 y $35.69 respectivamente, y se indicaron los rangos de precios de ejecuci贸n para cada lote. Tras estas ventas, la persona informante pose铆a beneficiariamente 17.462 acciones (propiedad directa). El informe se帽ala que las operaciones se realizaron conforme a un plan preestablecido y que el declarante puede facilitar detalles de cada operaci贸n bajo petici贸n.
Jonathan Zalevsky電� Nektar Therapeutics(NKTR)鞚� 斓滉碃 鞐瓣惮臧滊皽毂呾瀯鞛愲靹� 2025雲� 9鞗� 4鞚� Rule 10b5-1 瓯半灅瓿勴殟鞐� 霐半澕 須岇偓 氤错喌欤茧ゼ 雱� 彀 毵る弰頄堨姷雼堧嫟. 頃措嫻 瓯半灅霌れ潃 齑� 1,721欤�(793, 432, 189, 307)鞓�鞙茧┌, 臧�欷� 韽夑窢 臧�瓴╈潃 臧侁皝 $32.43, $33.60, $34.41, $35.69鞓�瓿� 臧� 氚办箻氤� 觳搓舶 臧�瓴� 氩旍渼臧� 瓿店皽霅橃棃鞀惦媹雼�. 鞚� 毵る弰 頉� 鞁犼碃鞚胳潃 歆侅爲 靻岇湢 旮办鞙茧 17,462欤�毳� 氤挫湢頃橁碃 鞛堨棃鞀惦媹雼�. 鞁犼碃靹滌棎電� 瓯半灅臧� 靷爠鞐� 靾橂霅� 瓿勴殟鞐� 霐半澕 鞚措（鞏挫鞚岇澊 氇呾嫓霅橃柎 鞛堨溂氅�, 鞁犼碃鞚胳潃 鞖旍箔 鞁� 臧滊硠 瓯半灅 靹鸽秬 雮挫棴鞚� 鞝滉车頃橁矤雼り碃 氚濏様鞀惦媹雼�.
Jonathan Zalevsky, Chief R&D Officer de Nektar Therapeutics (NKTR), a d茅clar茅 quatre ventes d'actions ordinaires de la soci茅t茅 le 04/09/2025, r茅alis茅es dans le cadre d'un plan de n茅gociation en vertu de la Rule 10b5-1. Les op茅rations ont port茅 au total sur 1 721 actions (lots de 793, 432, 189 et 307) aux prix moyens pond茅r茅s de $32.43, $33.60, $34.41 et $35.69 respectivement, avec les plages de prix d'ex茅cution pr茅cis茅es pour chaque lot. 脌 l'issue de ces ventes, le d茅clarant d茅tenait b茅n茅ficiairement 17 462 actions (possession directe). Le dossier indique que les transactions ont 茅t茅 ex茅cut茅es conform茅ment 脿 un plan pr茅茅tabli et que le d茅clarant peut fournir, sur demande, les d茅tails de chaque transaction.
Jonathan Zalevsky, Chief R&D Officer von Nektar Therapeutics (NKTR), meldete am 04.09.2025 vier Verk盲ufe von Stammaktien des Unternehmens im Rahmen eines Rule-10b5-1-Handelsplans. Die Transaktionen betrafen insgesamt 1.721 Aktien (Lose zu 793, 432, 189 und 307) mit gewichteten Durchschnittspreisen von jeweils $32.43, $33.60, $34.41 und $35.69; f眉r jedes Los wurden Ausf眉hrungspreisspannen angegeben. Nach diesen Verk盲ufen hielt die meldende Person wirtschaftlich 17.462 Aktien (Direktbesitz). Die Einreichung weist darauf hin, dass die Trades gem盲脽 einem vorab festgelegten Plan ausgef眉hrt wurden und dass der Melder auf Anfrage detaillierte Angaben zu den einzelnen Transaktionen zur Verf眉gung stellt.
- Sales were executed under a Rule 10b5-1 trading plan, which supports that transactions were pre-scheduled and reduces concerns about opportunistic timing.
- Filing discloses weighted-average prices and price ranges and offers to provide full trade-level details on request, indicating transparency.
- The reporting person sold 1,721 shares on 09/04/2025, reducing direct beneficial ownership to 17,462 shares, which may be viewed negatively by some investors.
- Multiple sale lots on the same day could attract attention despite being under a 10b5-1 plan.
Insights
TL;DR: Insider sales were conducted under a pre-set 10b5-1 plan, which typically reduces questions about timing and intent.
The report shows the Chief R&D Officer executed four dispositions totaling 1,721 shares on a single day under a Rule 10b5-1 plan. Use of a 10b5-1 plan is governance-positive because it evidences pre-approval and is designed to limit claims of opportunistic trading. The filing also discloses weighted-average prices and offers to provide specific trade-level details, increasing transparency for investors and regulators.
TL;DR: The insider sale reduced direct holdings but is routine given the documented 10b5-1 plan; not clearly material to valuation.
The aggregate sale size (1,721 shares) and resulting holding (17,462 shares) are modest absolute amounts based on this filing alone. Prices ranged from about $32.08 to $36.26 across lots as disclosed in ranges; reported weighted-average prices are provided. There is no indication of derivative transactions or other contemporaneous insider activity in this Form 4. Absent larger context on total outstanding insider holdings or company market cap, these disposals appear routine rather than materially value-moving.
Jonathan Zalevsky, Chief R&D Officer di Nektar Therapeutics (NKTR), ha effettuato quattro vendite di azioni ordinarie della societ脿 il 04/09/2025 nell'ambito di un piano di negoziazione ai sensi della Rule 10b5-1. Le operazioni hanno riguardato complessivamente 1.721 azioni (lotti da 793, 432, 189 e 307) con prezzi medi ponderati rispettivamente di $32.43, $33.60, $34.41 e $35.69, e sono stati indicati i range dei prezzi di esecuzione per ciascun lotto. Dopo queste cessioni, la persona che ha presentato la comunicazione possedeva beneficiariamente 17.462 azioni (possesso diretto). La comunicazione specifica che le operazioni sono state eseguite conformemente a un piano preesistente e che il dichiarante 猫 disponibile a fornire i dettagli di ciascuna operazione su richiesta.
Jonathan Zalevsky, Director de I&D de Nektar Therapeutics (NKTR), registr贸 cuatro ventas de acciones ordinarias de la compa帽铆a el 04/09/2025 dentro de un plan de negociaci贸n conforme a la Regla 10b5-1. Las transacciones dispensaron un total de 1.721 acciones (lotes de 793, 432, 189 y 307) con precios promedio ponderados de $32.43, $33.60, $34.41 y $35.69 respectivamente, y se indicaron los rangos de precios de ejecuci贸n para cada lote. Tras estas ventas, la persona informante pose铆a beneficiariamente 17.462 acciones (propiedad directa). El informe se帽ala que las operaciones se realizaron conforme a un plan preestablecido y que el declarante puede facilitar detalles de cada operaci贸n bajo petici贸n.
Jonathan Zalevsky電� Nektar Therapeutics(NKTR)鞚� 斓滉碃 鞐瓣惮臧滊皽毂呾瀯鞛愲靹� 2025雲� 9鞗� 4鞚� Rule 10b5-1 瓯半灅瓿勴殟鞐� 霐半澕 須岇偓 氤错喌欤茧ゼ 雱� 彀 毵る弰頄堨姷雼堧嫟. 頃措嫻 瓯半灅霌れ潃 齑� 1,721欤�(793, 432, 189, 307)鞓�鞙茧┌, 臧�欷� 韽夑窢 臧�瓴╈潃 臧侁皝 $32.43, $33.60, $34.41, $35.69鞓�瓿� 臧� 氚办箻氤� 觳搓舶 臧�瓴� 氩旍渼臧� 瓿店皽霅橃棃鞀惦媹雼�. 鞚� 毵る弰 頉� 鞁犼碃鞚胳潃 歆侅爲 靻岇湢 旮办鞙茧 17,462欤�毳� 氤挫湢頃橁碃 鞛堨棃鞀惦媹雼�. 鞁犼碃靹滌棎電� 瓯半灅臧� 靷爠鞐� 靾橂霅� 瓿勴殟鞐� 霐半澕 鞚措（鞏挫鞚岇澊 氇呾嫓霅橃柎 鞛堨溂氅�, 鞁犼碃鞚胳潃 鞖旍箔 鞁� 臧滊硠 瓯半灅 靹鸽秬 雮挫棴鞚� 鞝滉车頃橁矤雼り碃 氚濏様鞀惦媹雼�.
Jonathan Zalevsky, Chief R&D Officer de Nektar Therapeutics (NKTR), a d茅clar茅 quatre ventes d'actions ordinaires de la soci茅t茅 le 04/09/2025, r茅alis茅es dans le cadre d'un plan de n茅gociation en vertu de la Rule 10b5-1. Les op茅rations ont port茅 au total sur 1 721 actions (lots de 793, 432, 189 et 307) aux prix moyens pond茅r茅s de $32.43, $33.60, $34.41 et $35.69 respectivement, avec les plages de prix d'ex茅cution pr茅cis茅es pour chaque lot. 脌 l'issue de ces ventes, le d茅clarant d茅tenait b茅n茅ficiairement 17 462 actions (possession directe). Le dossier indique que les transactions ont 茅t茅 ex茅cut茅es conform茅ment 脿 un plan pr茅茅tabli et que le d茅clarant peut fournir, sur demande, les d茅tails de chaque transaction.
Jonathan Zalevsky, Chief R&D Officer von Nektar Therapeutics (NKTR), meldete am 04.09.2025 vier Verk盲ufe von Stammaktien des Unternehmens im Rahmen eines Rule-10b5-1-Handelsplans. Die Transaktionen betrafen insgesamt 1.721 Aktien (Lose zu 793, 432, 189 und 307) mit gewichteten Durchschnittspreisen von jeweils $32.43, $33.60, $34.41 und $35.69; f眉r jedes Los wurden Ausf眉hrungspreisspannen angegeben. Nach diesen Verk盲ufen hielt die meldende Person wirtschaftlich 17.462 Aktien (Direktbesitz). Die Einreichung weist darauf hin, dass die Trades gem盲脽 einem vorab festgelegten Plan ausgef眉hrt wurden und dass der Melder auf Anfrage detaillierte Angaben zu den einzelnen Transaktionen zur Verf眉gung stellt.
FAQ
What trades did Jonathan Zalevsky (NKTR) report on Form 4?
At what prices were the NKTR shares sold in the Form 4?
Did the Form 4 indicate these trades were part of a 10b5-1 plan?
How many NKTR shares does the reporting person own after these transactions?
Are there any derivative transactions reported in this Form 4?
